Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.92
SUPERNUS PHARMACEUTICALS, INC. incurred revolving credit of up to $150,000,000.00 with UBS Bank USA at Fixed rate: UBS Fixed Funding Rate + applicable Percentage Spread; Variable rate maturing Not explicitly stated; payable on demand or upon default.
- Instrument
- revolving credit
- Principal
- up to $150,000,000.00
- Counterparty
- UBS Bank USA
- Rate
- Fixed rate: UBS Fixed Funding Rate + applicable Percentage Spread; Variable rate
- Maturity
- Not explicitly stated; payable on demand or upon default
- Event
- incurrence
Exact text from the filing
On February 8, 2023, Supernus Pharmaceuticals, Inc. ( the “Company”) entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”). The Credit Line provides for a revolving line of credit of up to $150,000,000.00, which can be drawn at any time and will be used for general corporate purposes.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
SUPERNUS PHARMACEUTICALS, INC. entered into Credit Line with UBS Bank USA valued at $150,000,000.00 (effective 2023-02-08).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- UBS Bank USA
- Value
- $150,000,000.00
- Effective
- 2023-02-08
Exact text from the filing
On February 8, 2023, Supernus Pharmaceuticals, Inc. ( the “Company”) entered into a credit line agreement (the “Credit Line”) with UBS Bank USA (“UBS”). The Credit Line provides for a revolving line of credit of up to $150,000,000.00
View on SEC.gov